Detail akcie Lyell Immunphrm Rg online

Business Summary: Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Lyell Immunopharma Inc revenues decreased 40% to $30K. Net loss decreased 11% to $133.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Biotechnology & Medical Research segment loss decrease of 10% to $141.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$11.84 to -$8.55.